You are here
NDA Submitted for Genasense in Advanced Melanoma
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced cell death. By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatments. Based on preclinical and clinical studies that demonstrate anti-tumor effects in a broad range of cancers, Genta is studying Genasense in multiple, late-stage randomized and non-randomized clinical trials, including multiple myeloma, chronic lymphocytic leukemia, non-small cell lung cancer, small cell lung cancer, and prostate cancer.
About Malignant Melanoma
Malignant melanoma is the most deadly form of skin cancer. The incidence of this disease is increasing by approximately 4% annually in the US. In 2003, the American Cancer Society estimates more than 54,000 cases of malignant melanoma will have been diagnosed. Melanoma is the number one cause of cancer death in women aged 25 to 29.
Source: Genta Incorporated